Jefferies Financial Group Upgrades Pediatrix Medical Group (NYSE:MD) to “Buy”

Pediatrix Medical Group (NYSE:MD) was upgraded by investment analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm currently has a $14.00 target price on the stock, up from their prior target price of $8.00. Jefferies Financial Group’s target price would indicate a potential upside of 24.33% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Truist Financial lifted their target price on Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target on the stock in a report on Friday, June 7th. Finally, UBS Group boosted their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.30.

Pediatrix Medical Group Stock Down 0.9 %

MD stock opened at $11.26 on Thursday. The company has a market cap of $947.50 million, a PE ratio of -13.25, a price-to-earnings-growth ratio of 1.64 and a beta of 1.56. The business has a 50-day simple moving average of $10.04 and a 200 day simple moving average of $8.88. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $13.01. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The business had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. During the same quarter in the previous year, the firm earned $0.37 earnings per share. Pediatrix Medical Group’s revenue for the quarter was up .7% compared to the same quarter last year. Sell-side analysts anticipate that Pediatrix Medical Group will post 1.18 EPS for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In related news, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares in the company, valued at $343,783.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the transaction, the director now directly owns 30,805 shares in the company, valued at $343,783.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,100 shares of company stock worth $701,889. Insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several institutional investors have recently added to or reduced their stakes in MD. nVerses Capital LLC acquired a new position in shares of Pediatrix Medical Group during the second quarter worth approximately $31,000. Innealta Capital LLC bought a new stake in Pediatrix Medical Group during the second quarter worth $33,000. Nisa Investment Advisors LLC grew its holdings in Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after buying an additional 1,524 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Pediatrix Medical Group during the second quarter worth $72,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Pediatrix Medical Group during the second quarter worth $81,000. 97.71% of the stock is owned by institutional investors and hedge funds.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.